The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of nab-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
 
Michael J. Demeure
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Loxo/Lilly; OnCusp Therapeutics; Orphagen Pharmaceuticals; Pfizer; TD2; Theralink
(OPTIONAL) Uncompensated Relationships - transmed7
 
Allen Lee Cohn
Honoraria - Amgen
Expert Testimony - Department of Justice
 
Tara Elisabeth Seery
Employment - Chan Soon-Shiong Institute for Advanced Health; Hoag
Consulting or Advisory Role - Bayer; ipsen
Speakers' Bureau - Bayer; Ipsen
 
Li Ding
Employment - AADi
Stock and Other Ownership Interests - AADi
 
Willis H. Navarro
Employment - AADi; Atara Biotherapeutics
Stock and Other Ownership Interests - Atara Biotherapeutics; bluebird bio; Moderna Therapeutics; Novo Nordisk; Pfizer
Consulting or Advisory Role - Imago Pharma
 
Andrew Scott Paulson
Employment - Day One Biopharmaceuticals (I)
Stock and Other Ownership Interests - Actinium Pharmaceuticals
Honoraria - Array BioPharma; Cardinal Health; Curio Science
Consulting or Advisory Role - AADi; Advanced Accelerator Applications; Amgen; Array BioPharma; Astellas Pharma; AstraZeneca; Bayer; Bristol Myers Squibb; Eisai; EMD Serono; EMD Serono; Exelixis; Exelixis; Exelixis; Hutchison MediPharma; Incyte; Ipsen; Jazz Pharmaceuticals; Lilly; Mirati Therapeutics; Novartis; Pfizer; QED Therapeutics; Seagen; SERVIER; Stromatis Pharma; Takeda
Speakers' Bureau - Ideo Oncology
Research Funding - AstraZeneca (Inst); Bayer (Inst); BioNTech SE (Inst); bristol myers squibb (Inst); Buzzard Pharmaceuticals; Camurus (Inst); Camurus (Inst); Deciphera (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gritstone Bio (Inst); Hutchison MediPharma (Inst); incyte (Inst); Innovative Cellular Therapeutics Co (Inst); Inspirna (Inst); Ipsen (Inst); ITM Oncologics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Regenxbio (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sotio (Inst); Taiho Pharmaceutical (Inst); Tempus (Inst); TransThera Biosciences (Inst); Zentalis (Inst)
Travel, Accommodations, Expenses - AADi; Camurus; Mirati Therapeutics; Nucana; Pfizer